Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGomez-Centeno, Antonio
dc.contributor.authorRubio-Romero, Esteban
dc.contributor.authorOvalles, Juan Gabriel
dc.contributor.authorManrique-Arija, Sara
dc.contributor.authorMarsal-Barril, Sara
dc.contributor.authorAmarelo-Ramos, Juan
dc.contributor.authorDel Pino-Montes, Javier
dc.contributor.authorMuñoz-Fernández, Santiago
dc.contributor.authorBustabad, Sagrario
dc.contributor.authorBarbazán-Álvarez, Ceferino
dc.identifier.citationRheumatol Int.2019;(39)12:2015-2024
dc.description.abstractTo describe the clinical and therapeutic management of rheumatoid arthritis (RA) patients with biological disease-modifying antirheumatic drugs (bDMARDs), alone or in combination with conventional synthetic DMARDs (csDMARDs), as well as analysing changes over time in bDMARD use. An observational, retrospective, multicentre study was conducted in the rheumatology departments of 10 public Spanish hospitals. Patients with RA treated with bDMARDs at baseline who had medical records available in the data collection period 2013-2016 were included. All visits to rheumatology departments recording any type of bDMARD modification (dose, etc.) were collected. Clinical characteristics, concomitant treatment, resource use, work productivity and quality of life (QoL) were recorded. 128 patients were included: 81 received first-line bDMARD treatment, 28 second-line bDMARD treatment and 19 received third or later lines. Mean study follow-up was 4.1 years. Assessment of DAS28 was available in 54.6% of visits. At baseline, 48.7% of patients had moderate-high disease activity. At final observation, 69.5% of patients continued with the first bDMARD. Tumour necrosis factor blockers were administered to 85.2% of patients in first line, 45.7% in second line and 18.1% in third or later lines. At final observation, 80.2% of patients still felt pain/discomfort. As expected, those with higher disease activity had higher loss of work productivity and lower QoL, as assessed by DAS28, than patients with lower disease activity. Drugs represented 82.6% of the total cost. In this Spanish cohort of 128 patients, most patients remained on the first prescribed bDMARD, despite remaining signs and symptoms.
dc.subjectBiological disease-modifying antirheumatic drugs
dc.subjectRheumatoid arthritis
dc.subject.meshAntirheumatic Agents
dc.subject.meshArthritis, Rheumatoid
dc.subject.meshBiological Products
dc.subject.meshDrug Therapy, Combination
dc.subject.meshMiddle Aged
dc.subject.meshQuality of Life
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.titleClinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
dc.identifier.journalRheumatology international
dc.identifier.journalabbreviationRheumatol Int
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
Appears in Collections:Hospitales > H. U. Infanta Sofía > Artículos

Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.